[90Y-ibritumomab tiuxetan in patients with follicular lymphoma relapsing or refractory to rituximab].
Radioimmunotherapy is a new antineoplastic treatment modality combining the effects of irradiation and monoclonal antibodies. 90Y-ibritumomab tiuxetan is a monoclonal antibody directed against the CD20 antigen to which a radioactive isotope of yttrium is attached, used for treating follicular lymphomas (FL). Using this compound we treated 8 patients with FL relapsing or refractory to combinations of rituximab and chemotherapy. Severe neutropenia developed in 5, and severe thrombocytopenia and anemia in 3 patients. Serious infections developed in 2 patients, one died. Six patients responded to treatment, 4 are still in remission after a median follow-up of 15 months, 2 died of lymphoma. Best response was achieved in low-risk patients with a low tumor burden. 90Y-ibritumomab tiuxetan is an effective treatment for FL with significant hematological toxicity and a high price.
Aurer
Igor
I
Zavod za hematologiju, Klinike za unutrasnje bolesti, KBC-a Rebro i Medicinskog fakulteta Sveucilista u Zagrebu. aurer@mef.hr
Huić
Drazen
D
Zuvić
Marijan
M
Sever-Prebilić
Mirjana
M
Ajduković
Radmila
R
Radman
Ivo
I
Skare-Librenjak
Ljubica
L
Ostojić-Kolonić
Slobodanka
S
Labar
Boris
B
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20 / Q000276:immunology; D004351:Drug Resistance; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy; D008224:Lymphoma, Follicular / Q000188:drug therapy / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D000069283:Rituximab; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018951:Antigens, CD20; D015021:Yttrium Radioisotopes; D000069283:Rituximab; C422802:ibritumomab tiuxetan